Published in Am J Physiol Heart Circ Physiol on August 26, 2005
Measurement of Matrix Metalloproteinase Activation Post Myocardial Infarction | NCT00576121
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
IL-10 inhibits inflammation and attenuates left ventricular remodeling after myocardial infarction via activation of STAT3 and suppression of HuR. Circ Res (2008) 2.01
Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res (2012) 1.94
Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol (2012) 1.69
Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg (2012) 1.49
Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics (2010) 1.42
Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) (2013) 1.41
Cardiac aging: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal (2012) 1.40
Mice that lack matrix metalloproteinase-9 display delayed wound healing associated with delayed reepithelization and disordered collagen fibrillogenesis. Matrix Biol (2009) 1.40
Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther (2010) 1.39
Membrane-associated matrix proteolysis and heart failure. Circ Res (2013) 1.35
Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol (2009) 1.31
Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res (2008) 1.27
PET and SPECT in cardiovascular molecular imaging. Nat Rev Cardiol (2009) 1.26
Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther (2013) 1.21
Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure. J Appl Physiol (1985) (2011) 1.18
CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol (2011) 1.13
MMP-2/TIMP-2/TIMP-4 versus MMP-9/TIMP-3 in transition from compensatory hypertrophy and angiogenesis to decompensatory heart failure. Arch Physiol Biochem (2010) 1.12
Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal (2011) 1.09
Absence of regeneration in the MRL/MpJ mouse heart following infarction or cryoinjury. Cardiovasc Pathol (2007) 1.05
Helix-loop-helix protein p8, a transcriptional regulator required for cardiomyocyte hypertrophy and cardiac fibroblast matrix metalloprotease induction. Mol Cell Biol (2006) 1.04
Matrix metalloproteinase-9 delays wound healing in a murine wound model. Surgery (2009) 1.04
Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics (2013) 1.01
Analysis of angiogenesis induced by local IGF-1 expression after myocardial infarction using microSPECT-CT imaging. J Mol Cell Cardiol (2009) 1.01
Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair (2013) 0.99
Salvianolic acid B functioned as a competitive inhibitor of matrix metalloproteinase-9 and efficiently prevented cardiac remodeling. BMC Pharmacol (2010) 0.97
MMP-9 gene deletion mitigates microvascular loss in a model of ischemic acute kidney injury. Am J Physiol Renal Physiol (2011) 0.97
Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res (2012) 0.93
Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J Mol Cell Cardiol (2014) 0.91
Caveolin-1 deletion exacerbates cardiac interstitial fibrosis by promoting M2 macrophage activation in mice after myocardial infarction. J Mol Cell Cardiol (2014) 0.90
P. gingivalis lipopolysaccharide intensifies inflammation post-myocardial infarction through matrix metalloproteinase-9. J Mol Cell Cardiol (2014) 0.90
Molecular imaging of angiogenesis with SPECT. Eur J Nucl Med Mol Imaging (2010) 0.90
Decreased metalloprotease 9 induction, cardiac fibrosis, and higher autophagy after pressure overload in mice lacking the transcriptional regulator p8. Am J Physiol Cell Physiol (2011) 0.89
MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction. Am J Pathol (2012) 0.89
Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol (2011) 0.88
Deriving a cardiac ageing signature to reveal MMP-9-dependent inflammatory signalling in senescence. Cardiovasc Res (2015) 0.88
Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal (2014) 0.88
Targeted molecular imaging of angiogenesis in PET and SPECT: a review. Yale J Biol Med (2012) 0.87
Myocardial Infarction Superimposed on Aging: MMP-9 Deletion Promotes M2 Macrophage Polarization. J Gerontol A Biol Sci Med Sci (2015) 0.87
Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl (2014) 0.86
CD36 Is a Matrix Metalloproteinase-9 Substrate That Stimulates Neutrophil Apoptosis and Removal During Cardiac Remodeling. Circ Cardiovasc Genet (2015) 0.85
CD13 is essential for inflammatory trafficking and infarct healing following permanent coronary artery occlusion in mice. Cardiovasc Res (2013) 0.85
Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res (2014) 0.84
Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. J Mol Cell Cardiol (2015) 0.84
Circulating Porphyromonas gingivalis lipopolysaccharide resets cardiac homeostasis in mice through a matrix metalloproteinase-9-dependent mechanism. Physiol Rep (2013) 0.84
Cerebral ischaemia and matrix metalloproteinase-9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. J Cell Mol Med (2013) 0.84
ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol (2007) 0.82
Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol (2015) 0.82
Impaired vascular remodeling after endothelial progenitor cell transplantation in MMP9-deficient mice suffering cortical cerebral ischemia. J Cereb Blood Flow Metab (2015) 0.80
Plasma fractionation enriches post-myocardial infarction samples prior to proteomics analysis. Int J Proteomics (2012) 0.80
Desregulated microRNAs in aging-related heart failure. Front Genet (2014) 0.80
A conceptual cellular interaction model of left ventricular remodelling post-MI: dynamic network with exit-entry competition strategy. BMC Syst Biol (2010) 0.80
Obese and diabetic KKAy mice show increased mortality but improved cardiac function following myocardial infarction. Cardiovasc Pathol (2013) 0.79
Knockdown of EMMPRIN improves adverse remodeling mediated by IL-18 in the post-infarcted heart. Am J Transl Res (2015) 0.79
Building a better infarct: Modulation of collagen cross-linking to increase infarct stiffness and reduce left ventricular dilation post-myocardial infarction. J Mol Cell Cardiol (2015) 0.78
Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. Methods Mol Biol (2013) 0.78
The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction. IUBMB Life (2015) 0.78
Integrative computational and experimental approaches to establish a post-myocardial infarction knowledge map. PLoS Comput Biol (2014) 0.77
The role of molecular imaging in the evaluation of myocardial and peripheral angiogenesis. Ann Nucl Med (2015) 0.77
Defining the sham environment for post-myocardial infarction studies in mice. Am J Physiol Heart Circ Physiol (2016) 0.77
Deletion of thioredoxin-interacting protein improves cardiac inotropic reserve in the streptozotocin-induced diabetic heart. Am J Physiol Heart Circ Physiol (2016) 0.77
MMP-9 signaling in the left ventricle following myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.76
Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function. J Cardiovasc Pharmacol (2009) 0.76
Matrix metalloproteinase-9-dependent mechanisms of reduced contractility and increased stiffness in the aging heart. Proteomics Clin Appl (2015) 0.76
Ablation of Matrix Metalloproteinase-9 Prevents Cardiomyocytes Contractile Dysfunction in Diabetics. Front Physiol (2016) 0.76
Early matrix metalloproteinase-9 inhibition post-myocardial infarction worsens cardiac dysfunction by delaying inflammation resolution. J Mol Cell Cardiol (2016) 0.76
Mathematical modeling of cardiac growth and remodeling. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
The Long-Term Consumption of Ginseng Extract Reduces the Susceptibility of Intermediate-Aged Hearts to Acute Ischemia Reperfusion Injury. PLoS One (2015) 0.75
Transgenic overexpression of macrophage matrix metalloproteinase-9 exacerbates age-related cardiac hypertrophy, vessel rarefaction, inflammation, and fibrosis. Am J Physiol Heart Circ Physiol (2016) 0.75
Using the laws of thermodynamics to understand how matrix metalloproteinases coordinate the myocardial response to injury. Metalloproteinases Med (2015) 0.75
Tipping the extracellular matrix balance during heart failure progression: do we always go right? Cardiology (2010) 0.75
SPECT and PET imaging of angiogenesis and arteriogenesis in pre-clinical models of myocardial ischemia and peripheral vascular disease. Eur J Nucl Med Mol Imaging (2016) 0.75
Ataxia telangiectasia-mutated kinase deficiency exacerbates left ventricular dysfunction and remodeling late after myocardial infarction. Am J Physiol Heart Circ Physiol (2016) 0.75
Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med (2007) 8.06
Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell (2013) 6.35
Stem-cell therapy for cardiac disease. Nature (2008) 5.75
Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest (2004) 5.68
Mammalian heart renewal by pre-existing cardiomyocytes. Nature (2012) 5.56
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest (2007) 4.31
Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell (2011) 3.49
Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science (2014) 3.37
Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell (2013) 3.35
TXNIP regulates peripheral glucose metabolism in humans. PLoS Med (2007) 3.27
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science (2014) 3.14
Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature (2012) 3.04
Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 2.90
Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation (2005) 2.89
Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest (2005) 2.80
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.75
Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail (2009) 2.72
Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol (2005) 2.66
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation (2003) 2.62
Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation (2003) 2.54
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 2.52
Differential effect of 180 degrees and 360 degrees acquisition orbits on the accuracy of SPECT imaging: quantitative evaluation in phantoms. J Nucl Med (2002) 2.35
Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem (2004) 2.35
Cell mechanics and mechanotransduction: pathways, probes, and physiology. Am J Physiol Cell Physiol (2004) 2.32
Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res (2007) 2.31
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.30
Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation (2009) 2.30
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem (2006) 2.15
Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation (2005) 2.14
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res (2005) 2.12
Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation (2004) 2.11
Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation (2007) 2.07
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
Intramyocardial fibroblast myocyte communication. Circ Res (2010) 1.98
Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation (2003) 1.95
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation (2008) 1.95
Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation (2003) 1.91
Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. Biomaterials (2007) 1.90
Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg (2011) 1.88
Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell (2013) 1.86
Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation (2005) 1.82
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest (2004) 1.82
Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg (2008) 1.82
Estimation of 3-D left ventricular deformation from medical images using biomechanical models. IEEE Trans Med Imaging (2002) 1.82
Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation (2005) 1.81
Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem (2002) 1.79
Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem (2007) 1.78
Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8-year retrospective cohort study. J Thorac Cardiovasc Surg (2006) 1.78
Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest (2005) 1.77
Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail (2009) 1.74
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation (2006) 1.69
Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem (2009) 1.69
Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol (2006) 1.68
Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res (2004) 1.68
Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation (2002) 1.67
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res (2002) 1.65
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation (2010) 1.64
Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci U S A (2003) 1.63
Custom design of the cardiac microenvironment with biomaterials. Circ Res (2005) 1.63
Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. Aging Cell (2008) 1.61
Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J Hypertens (2002) 1.61
Aprotinin in cardiac surgery: a review of conventional and novel mechanisms of action. Anesth Analg (2007) 1.57
Biomechanically induced gene iex-1 inhibits vascular smooth muscle cell proliferation and neointima formation. Circ Res (2003) 1.57
Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation (2004) 1.57
Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation (2011) 1.55
Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem (2012) 1.55